(From the Medical Laboratory and Services of the Massachusetts General
Hospital, Boston) (Received for publication, July 1, 1929) Though a number of investigators have studied the appearance of antibody and agglutinin during pneumococcus infection in man and in animals, it has seemed desirable to pursue the matter further. For this purpose, we have used blood obtained from patients with Types I, II and III pneumococcus pneumonia at the Massachusetts General Hospital and from the private practice of one of us. Through the kindness of Dr. H. A. Christian of the Peter Bent Brigham Hospital and Dr. W. H. Robey and his associates of the Boston City Hospital, we have also had the opportunity to investigate the blood of patients in these institutions. We are especially indebted to Dr. Maxwell Finland of the Boston City Hospital and to Dr. George Walker of the Peter Bent Brigham Hospital for obtaining blood from patients in these hospitals. We are indebted to Dr. Lloyd D. Felton of the Harvard Medical School for his kindness in furnishing virulent cultures of the pneumococcus and for many helpful suggestions.
Method
Tests for antibody were made by inoculating intraperitoneally each of 14 mice with 0.2 co. of the patient's serum plus 0.3 co. of one per cent peptone solution, and directly after this with dilutions of a highly virulent culture of pneumoeoccus of the same type as that found to be the cause of the pneumonia. For this purpose, seven dilutions of an eighteen hour beef heart broth culture of the organisms were made as follows:--i : 100, 1 : 1000, 1 : 10,000, 1 : 100,000, 1 : 1,000,000, 1 : 10,000,000
and 1 : 100,000,000 and 0.5 cc. of each of these dilutions injected into each of two mice.
The tests for antibody were thus done in duplicate. In addition, no serum was given to two mice used as controls, one receiving 0.5 cc. of 1:10,000,000 and the other the same amount of 1 : 100,000,000 dilution of the culture. All mice were observed for 96 hours. We have regarded the survival of 1 mouse of the series inoculated with the patient's serum and organisms as an indication of protection. This seems reasonable in view of the death of the control mice and the fact that in all patients whose blood was tested before treatment within the first 5 days of the illness no protection was found. We realize a possibility of error in this, but such error would change the finding in only 3 out of 57 patients.
Tests for agglutinin were made with suspensions of living or dead homologous pneumococci at varying dilutions (1:2, 1:4, 1:8, 1:16, 1:20, 1:40, 1:80, l:100, 1:200. 1:500) of the patient's serum according to the method of Arlyle Noble (3". Bact., 14, 287, Nov., 1927) , who uses small amounts of serum and concentrated suspensions of organisms. It was found that the tests were easier to read after a half hour of incubation, and this variation in the technique was made.
The blood of 57 patients was investigated for both antibody and agglutinin. On 46 of the series from two to fifteen tests were made. In the specifically treated cases the first sample of blood was taken before serum was given. Blood for subsequent tests on these cases was taken not sooner than eight hours after the administration of serum. Only 1 observation was made on 11 patients.
The results may be sketched as follows :-
Observations on Antibody in Pneumonia Time of appearance of antibody during the disease
Our observations confirm those of other investigators in the finding that antibody in untreated cases appears at or about the time of the fall in the temperature. Of 4.9 patients to whom no serum had been given to the time the test was made none were found to have protection before the sixth day. Of 6 patients not treated with serum and tested at the time of the temperature fall only 1 failed to show antibody. The earliest time of appearance in the untreated group was the sixth day in 2 patients in whom the temperature fell within the next twentyfour hours.
In the treated group protective substances were frequently demonstrated after the use of Felton's antibody at a time in the course of the disease when protection would otherwise not be expected.
Behavior of A ntibody during Convalescence and in Complicated Cases
Nineteen patients with antibody at the time of the fall in temperature were tested during convalescence. Protection was present in 8 from a few days to a week, in 2 into the second week, in 3 into the third, in 4 into the fourth, in 1 into the fifth and in 1 into the ninth week. In 11 of these cases no further tests were made. The remaining 8 showed that the antibody, previously present, was absent in 2 in the first, in 1 in the second, in 2 in the third, in 2 in the fifth and in 1 in the eighth week.
Four other patients who had had pneumonia 7 to 13 months previously, but had not been tested during the course of the disease, failed to show antibody.
In addition to the patients already referred to, 1 with unresolved pneumonia was found to have protection from the fifth to at least the forty-ninth day after the onset of the disease. His febrile course lasted 43 days. One patient with pneumonia and empyema was first tested 3 weeks after the estimated onset of the illness. At this time, he had antibody which persisted for at least four weeks longer. Another patient had empyema following pneumonia and had developed antibody when first tested, but died three days later of pneumococcus endocarditis, eighty-six days after the onset of the illness.
In our small series the duration of antibody after the fall in the temperature was variable. There appears to be no difference in its duration in those with and those without specific treatment. In the treated group, early or late treatment seemed to have no influence on its persistence.
The explanation of the disappearance of antibody in certain cases and its persistence in others is not clear. The presence of an unresolved pneumonia, or such complications as empyema or pneumococcus endocarditis, may have been responsible in certain cases, but in others no explanation is apparent.
Relation of Antibody to the Outcome
Of 35 patients who showed antibody at some time during the course of the disease, 29 recovered and 6 died. Of the 29 who recovered, antibody was present at the time of the fall in the temperature in all. Of the 6 fatal cases, all were treated, none before the fifth day. One had empyema and pneumococcus endocarditis and another cardiac and renal complications. There were no obvious complications in the remaining four. All 6 had demonstrable antibody to within thirtysix hours of death.
Of 6 patients without protection during the course of the disease 5 died and 1 recovered. None were specifically treated. The patient who recovered failed to show antibody during the last three days of the disease and when tested five times during a subsequent period of twelve days.
Observations on A gglutinin in Pneumonia
The behavior of agglutinin was much the same as that of antibody. When present during the disease in patients without specific treatment it was first demonstrated at the time of the crisis or lysis. It was frequently demonstrated in specifically treated patients earlier than would otherwise be expected. It was present in all but 4 of 27 patients at the time of the fall in temperature. During the post-febrile period agglutinin was usually found to persist for a shorter period than did antibody.
Value of Tests for A gglutinin as an Indication of the Presence of Antibody during the Course of the Disease
Inasmuch as tests for agglutinin in the patient's blood are not difficult to perform the question arises whether the presence or absence of agg]utinin may be useful as an indication of the presence or absence of antibody and the control of dosage of specific serum. In an attempt to answer the question, we have correlated the findings with respect to these two substances in 32 patients. Agglutinin and antibody appeared simultaneously in 8. Agglutinin preceded antibody in 5 cases, in 3 of these by one day and in 2 by two days. In 2, agglutinin was present without antibody at any time during the course of the disease. Of the remaining 17 patients, in 9 antibody preceded agglutinin by one day in 3, by two days in 1, by three days in 4 and by four days in 1. In 8 patients antibody was present without demonstrable agglutinin in repeated tests.
Agglutinin may be present even in high titer without any demonstrable antibody and conversely there may be abundant protective substances without demonstrable agglutinin. In 7 of 32 patients the presence of agglutinin if interpreted.as an indication of the presence of antibody, would have led to an erroneous conclusion regarding treatment. Agglutinin, therefore, is unreliable as a control of dosage. The clinical aspects of the case seem to us a better means of judging the desirable amount of serum and the frequency with which it should be administered.
